NORTH WALES, Pa., and ATLANTA The U.S. respiratory therapy unit of Teva Pharmaceuticals, Teva Specialty Pharmaceuticals and UCB announced an agreement to co-commercialize Teva’s respiratory medicines.
The first product to be promoted is Teva’s ProAir HFA Inhalation Aerosol. ProAir HFA is the number-one branded hydrofluroalkane albuterol sulfate inhaler in the U.S.
The agreement will provide UCB future joint-promotion opportunities with other products in development by Teva Specialty Pharmaceuticals. Financial terms of the agreement were not disclosed.
“Over the last months we have undertaken a rich, strategic review globally across regions, therapy areas and business units,” said William Marth, president and chief executive officer of Teva North America. “The respiratory therapy area has been identified as a key growth area given the incidence of asthma, allergic rhinitis, and chronic obstructive pulmonary disease. Our collaboration with UCB, a company known for excellence in the respiratory market, will help us achieve a stronger presence in this growing therapeutic area.”